In this regard—and besides GBA1 genotyping—we suggest that screening for GBA2 mutations should be considered, together with analytical measurements of cholesterol glycosides in body fluids, as biomarkers for both PD risk and disease progression. Here, GBA1 is linked to Parkinson disease.